Tango Therapeutics Announces CEO Transition: Barbara Weber Steps Down, Malte Peters Appointed As Chief Executive Officer

Tango Therapeutics, Inc., a clinical-stage biotechnology company focused on developing the next generation of precision cancer therapies, announced the retirement of its Chief Executive Officer, Dr. Barbara Weber, effective January 8, 2026. Dr. Weber, the company’s founding CEO, will assume the role of Executive Chair for 2026 and will transition to Non-Executive Chair in 2027. 

She will be succeeded by Dr. Malte Peters, a distinguished leader with extensive experience in clinical development and corporate leadership, who has served on Tango’s Board of Directors since 2018 and will guide the company into its next phase of growth. In her new role, Dr. Weber will continue to work closely with the senior management team, supporting strategic priorities and ensuring a seamless transition while maintaining focus on ongoing clinical programs. In addition, Alexis Borisy, the current Board Chair, will transition to the role of Lead Independent Director.

Reflecting on her tenure, Dr. Weber said that it had been an extraordinary privilege to build and lead Tango from its inception. She expressed pride in the team’s accomplishments over the past eight years, particularly advancing vopimetostat into its first registrational trial and initiating combination studies with the potential to be transformative for patients. 

She added that having worked with Dr. Peters for over 15 years, she had full confidence in his leadership and expertise to guide Tango’s clinical-stage pipeline into pivotal studies and eventual commercialization. Alexis Borisy also expressed the Board’s gratitude for Dr. Weber’s vision and dedication, noting that her leadership had been transformative for the company and that they were confident in Dr. Peters’ ability to lead the organization forward.

Dr. Peters, in turn, said he was honored to join Tango’s executive team at such a pivotal time and looked forward to working closely with Dr. Weber, the Board, and the management team. He highlighted the strong foundation laid by Dr. Weber and the team and emphasized his commitment to advancing the company’s clinical programs and shared vision for the future. An accomplished industry veteran, Dr. Peters brings extensive experience in both early- and late-stage clinical development, having led global teams and delivered innovative therapies to patients. 

Prior to joining Tango, he served as Chief Research and Development Officer at MorphoSys AG and previously as Chief Development Officer and board member, overseeing the global regulatory approval of Monjuvi in combination with lenalidomide for diffuse large B cell lymphoma. Earlier in his career, he held senior clinical leadership positions at Sandoz International and Novartis, including Clinical Head and Site Head for Oncology Translational Medicine in Basel and East Hanover. Dr. Peters earned his medical degree from Freie Universität Berlin, Germany, with clinical training at the Universities of Padova, Italy, and Bochum and Berlin, Germany.

Tango Therapeutics also confirmed its clinical guidance for 2026, which includes initial safety and efficacy data from combination trials of vopimetostat with daraxonrasib and vopimetostat with zoldonrasib in Phase 1/2 studies, a Phase 1/2 clinical data update for vopimetostat monotherapy in lung cancer, the initiation of a pivotal second-line pancreatic cancer study for vopimetostat monotherapy, and initial safety and efficacy data from the TNG456 monotherapy Phase 1/2 trial. With this strengthened leadership team, Tango is well positioned to advance its clinical pipeline and continue its mission to deliver precision cancer therapies that improve patient outcomes.